These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
815 related articles for article (PubMed ID: 32585135)
1. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Huo J; Zhao Y; Ren J; Zhou D; Duyvesteyn HME; Ginn HM; Carrique L; Malinauskas T; Ruza RR; Shah PNM; Tan TK; Rijal P; Coombes N; Bewley KR; Tree JA; Radecke J; Paterson NG; Supasa P; Mongkolsapaya J; Screaton GR; Carroll M; Townsend A; Fry EE; Owens RJ; Stuart DI Cell Host Microbe; 2020 Sep; 28(3):445-454.e6. PubMed ID: 32585135 [TBL] [Abstract][Full Text] [Related]
2. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645 [TBL] [Abstract][Full Text] [Related]
3. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Huo J; Le Bas A; Ruza RR; Duyvesteyn HME; Mikolajek H; Malinauskas T; Tan TK; Rijal P; Dumoux M; Ward PN; Ren J; Zhou D; Harrison PJ; Weckener M; Clare DK; Vogirala VK; Radecke J; Moynié L; Zhao Y; Gilbert-Jaramillo J; Knight ML; Tree JA; Buttigieg KR; Coombes N; Elmore MJ; Carroll MW; Carrique L; Shah PNM; James W; Townsend AR; Stuart DI; Owens RJ; Naismith JH Nat Struct Mol Biol; 2020 Sep; 27(9):846-854. PubMed ID: 32661423 [TBL] [Abstract][Full Text] [Related]
4. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Zhou D; Duyvesteyn HME; Chen CP; Huang CG; Chen TH; Shih SR; Lin YC; Cheng CY; Cheng SH; Huang YC; Lin TY; Ma C; Huo J; Carrique L; Malinauskas T; Ruza RR; Shah PNM; Tan TK; Rijal P; Donat RF; Godwin K; Buttigieg KR; Tree JA; Radecke J; Paterson NG; Supasa P; Mongkolsapaya J; Screaton GR; Carroll MW; Gilbert-Jaramillo J; Knight ML; James W; Owens RJ; Naismith JH; Townsend AR; Fry EE; Zhao Y; Ren J; Stuart DI; Huang KA Nat Struct Mol Biol; 2020 Oct; 27(10):950-958. PubMed ID: 32737466 [TBL] [Abstract][Full Text] [Related]
5. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513 [TBL] [Abstract][Full Text] [Related]
6. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838 [TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates. Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177 [TBL] [Abstract][Full Text] [Related]
8. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies. Hussain A; Hasan A; Nejadi Babadaei MM; Bloukh SH; Chowdhury MEH; Sharifi M; Haghighat S; Falahati M Biomed Pharmacother; 2020 Oct; 130():110559. PubMed ID: 32768882 [TBL] [Abstract][Full Text] [Related]
9. A spike with which to beat COVID-19? Alam N; Higgins MK Nat Rev Microbiol; 2020 Aug; 18(8):414. PubMed ID: 32415242 [TBL] [Abstract][Full Text] [Related]
10. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance. Robson B Comput Biol Med; 2020 Jun; 121():103749. PubMed ID: 32568687 [TBL] [Abstract][Full Text] [Related]
11. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192 [TBL] [Abstract][Full Text] [Related]
12. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Barnes CO; West AP; Huey-Tubman KE; Hoffmann MAG; Sharaf NG; Hoffman PR; Koranda N; Gristick HB; Gaebler C; Muecksch F; Lorenzi JCC; Finkin S; Hägglöf T; Hurley A; Millard KG; Weisblum Y; Schmidt F; Hatziioannou T; Bieniasz PD; Caskey M; Robbiani DF; Nussenzweig MC; Bjorkman PJ Cell; 2020 Aug; 182(4):828-842.e16. PubMed ID: 32645326 [TBL] [Abstract][Full Text] [Related]
13. A human monoclonal antibody blocking SARS-CoV-2 infection. Wang C; Li W; Drabek D; Okba NMA; van Haperen R; Osterhaus ADME; van Kuppeveld FJM; Haagmans BL; Grosveld F; Bosch BJ Nat Commun; 2020 May; 11(1):2251. PubMed ID: 32366817 [TBL] [Abstract][Full Text] [Related]
14. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Shi R; Shan C; Duan X; Chen Z; Liu P; Song J; Song T; Bi X; Han C; Wu L; Gao G; Hu X; Zhang Y; Tong Z; Huang W; Liu WJ; Wu G; Zhang B; Wang L; Qi J; Feng H; Wang FS; Wang Q; Gao GF; Yuan Z; Yan J Nature; 2020 Aug; 584(7819):120-124. PubMed ID: 32454512 [TBL] [Abstract][Full Text] [Related]
15. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Tai W; Zhang X; He Y; Jiang S; Du L Antiviral Res; 2020 Jul; 179():104820. PubMed ID: 32405117 [TBL] [Abstract][Full Text] [Related]
16. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice. Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978 [TBL] [Abstract][Full Text] [Related]
17. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies. Papageorgiou AC; Mohsin I Cells; 2020 Oct; 9(11):. PubMed ID: 33105869 [TBL] [Abstract][Full Text] [Related]
18. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Yuan M; Wu NC; Zhu X; Lee CD; So RTY; Lv H; Mok CKP; Wilson IA Science; 2020 May; 368(6491):630-633. PubMed ID: 32245784 [TBL] [Abstract][Full Text] [Related]
19. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana. Rattanapisit K; Shanmugaraj B; Manopwisedjaroen S; Purwono PB; Siriwattananon K; Khorattanakulchai N; Hanittinan O; Boonyayothin W; Thitithanyanont A; Smith DR; Phoolcharoen W Sci Rep; 2020 Oct; 10(1):17698. PubMed ID: 33077899 [TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Datta PK; Liu F; Fischer T; Rappaport J; Qin X Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]